| Rachel Fasson Esposito, DO | |
|
599 N Church St, Suite 200, Mt Pleasant, PA 15666-1004 | |
| (724) 542-5349 | |
| (724) 542-4658 |
| Full Name | Rachel Fasson Esposito |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 599 N Church St, Mt Pleasant, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770577793 | NPI | - | NPPES |
| 101936986 | Medicaid | PA | |
| 101287842 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS012524 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Excela Health Home Care & Hospice | Greensburg, PA | Home health agency |
| Amedisys Home Health Of Pa | Uniontown, PA | Home health agency |
| Amedisys Hospice Of Pa | Uniontown, PA | Hospice |
| Excela Health - Frick Hospital | Mount pleasant, PA | Hospital |
| Excela Health Westmoreland Regional Hospital | Greensburg, PA | Hospital |
| Highlands Hospital | Connellsville, PA | Hospital |
| Excela Health Latrobe Hospital | Latrobe, PA | Hospital |
| Uniontown Hospital | Uniontown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Esposito Medical Associates Ltd | 8426324542 | 4 |
News Archive
A HIGHLY accurate urine test which can rule out bladder cancer with a negative-predictive value of 99% using a hospital laboratory's standard ELISA testing equipment is today being offered free to the NHS to help urologists clear the backlog of people waiting for a diagnosis and monitoring as a result of COVID-19 hospital closures.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A new analysis has found no evidence that children aged 6 to 11 years seeking a deceased donor lung transplant are disadvantaged in the current US lung allocation system. The findings, which are published in the American Journal of Transplantation, help inform ongoing discussions regarding potential changes to the nation's lung allocation policy.
The human brain is capable of a neural workaround that compensates for the buildup of beta-amyloid, a destructive protein associated with Alzheimer's disease, according to a new study led by researchers at the University of California, Berkeley.
› Verified 9 days ago
| Entity Name | Highlands Hospital And Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447443957 PECOS PAC ID: 2769460757 Enrollment ID: O20040707001195 |
News Archive
A HIGHLY accurate urine test which can rule out bladder cancer with a negative-predictive value of 99% using a hospital laboratory's standard ELISA testing equipment is today being offered free to the NHS to help urologists clear the backlog of people waiting for a diagnosis and monitoring as a result of COVID-19 hospital closures.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A new analysis has found no evidence that children aged 6 to 11 years seeking a deceased donor lung transplant are disadvantaged in the current US lung allocation system. The findings, which are published in the American Journal of Transplantation, help inform ongoing discussions regarding potential changes to the nation's lung allocation policy.
The human brain is capable of a neural workaround that compensates for the buildup of beta-amyloid, a destructive protein associated with Alzheimer's disease, according to a new study led by researchers at the University of California, Berkeley.
› Verified 9 days ago
| Entity Name | Esposito Medical Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386168680 PECOS PAC ID: 8426324542 Enrollment ID: O20171017003455 |
News Archive
A HIGHLY accurate urine test which can rule out bladder cancer with a negative-predictive value of 99% using a hospital laboratory's standard ELISA testing equipment is today being offered free to the NHS to help urologists clear the backlog of people waiting for a diagnosis and monitoring as a result of COVID-19 hospital closures.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A new analysis has found no evidence that children aged 6 to 11 years seeking a deceased donor lung transplant are disadvantaged in the current US lung allocation system. The findings, which are published in the American Journal of Transplantation, help inform ongoing discussions regarding potential changes to the nation's lung allocation policy.
The human brain is capable of a neural workaround that compensates for the buildup of beta-amyloid, a destructive protein associated with Alzheimer's disease, according to a new study led by researchers at the University of California, Berkeley.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Fasson Esposito, DO 599 N Church St, Suite 200, Mt Pleasant, PA 15666-1004 Ph: (724) 542-5349 | Rachel Fasson Esposito, DO 599 N Church St, Suite 200, Mt Pleasant, PA 15666-1004 Ph: (724) 542-5349 |
News Archive
A HIGHLY accurate urine test which can rule out bladder cancer with a negative-predictive value of 99% using a hospital laboratory's standard ELISA testing equipment is today being offered free to the NHS to help urologists clear the backlog of people waiting for a diagnosis and monitoring as a result of COVID-19 hospital closures.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A new analysis has found no evidence that children aged 6 to 11 years seeking a deceased donor lung transplant are disadvantaged in the current US lung allocation system. The findings, which are published in the American Journal of Transplantation, help inform ongoing discussions regarding potential changes to the nation's lung allocation policy.
The human brain is capable of a neural workaround that compensates for the buildup of beta-amyloid, a destructive protein associated with Alzheimer's disease, according to a new study led by researchers at the University of California, Berkeley.
› Verified 9 days ago
Manjusha Kad, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 525 W Main St, Mt Pleasant, PA 15666 Phone: 724-547-4536 Fax: 724-547-3799 | |
Emilio R Navarro, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 599 N Church St, Lower Level, Mt Pleasant, PA 15666 Phone: 724-542-8100 | |
Dr. Efren L Leonida, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: One Braddock Ave, Suite A, Mt Pleasant, PA 15666 Phone: 724-547-4565 Fax: 724-547-5811 | |
Molly Castille, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 508 S Church St Ste 100, Mt Pleasant, PA 15666 Phone: 724-547-4536 Fax: 724-547-3799 | |
Dr. William Mark Weisel, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 525 W Main St, Mt Pleasant, PA 15666 Phone: 724-547-4536 Fax: 724-547-3799 | |
Andrew Schleihauf, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 508 S Church St Ste 200, Mt Pleasant, PA 15666 Phone: 724-547-1208 Fax: 724-547-1207 |